公开(公告)号：US20040234600A1

公开(公告)日：2004-11-25

申请号：US10884744

申请日：2004-07-02

发明人： Sonya Merrill ,  Atul D. Ayer ,  Navjot Chadha ,  Anthony L. Kuczynski

IPC分类号： A61K009/22 ,  A61K031/485

CPC分类号： A61K9/0004 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K31/485

摘要： A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.

摘要翻译： 公开了用于治疗疼痛的氢吗啡酮组合物，氢吗啡酮剂型和用于给予氢吗啡酮的方法。

公开(公告)号：US20040230183A1

公开(公告)日：2004-11-18

申请号：US10781350

申请日：2004-02-18

发明人： Wisam Breegi ,  Pericles Calias ,  Anthony P. Adamis ,  David Shima ,  Emmett T. Cunningham

IPC分类号： A61K009/22

CPC分类号： A61F9/0017

摘要： The invention relates to the field of drug delivery devices. More particularly, the invention relates to implantable, refillable drug delivery devices which provide for drug delivery over sustained time periods. The present invention has particular application for ophthalmic drug delivery applications.

摘要翻译： 本发明涉及药物输送装置领域。 更具体地说，本发明涉及可持续的时间段提供药物输送的可植入的可重新填充的药物递送装置。 本发明特别适用于眼药物递送应用。

公开(公告)号：US20040225281A1

公开(公告)日：2004-11-11

申请号：US10867785

申请日：2004-06-15

申请人： MEDTRONIC MINIMED, INC.

发明人： Eric Lorenzen ,  John Gray ,  Robert Bosley

IPC分类号： A61K009/22

CPC分类号： A61M5/14216 ,  A61M5/14276 ,  A61M5/16877 ,  A61M2205/8212

摘要： A drive mechanism for delivery of infusion medium a coil capable of being electrically activated to provide an electromagnetic field. The coil surrounds a piston channel extending in an axial direction. The piston channel provides a passage for communication of infusion medium to an outlet chamber located at one end of the piston channel. An armature is located adjacent the coil, on one side of the axial channel. The armature is moveable toward a forward position, in response to the electromagnetic field produced by activation of the coil. A piston is located within the piston channel and is moveable axially within the channel to a forward position, in response to movement of the armature to its forward position. The armature and piston are moved toward a retracted position, when the coil is not energized. In the retracted position of the piston, a piston chamber is formed between the piston and a valve member and is filled with infusion medium. As the piston is moved to its forward position, the piston chamber volume is reduced and pressure within the piston chamber increases to a point where the pressure moves the valve member into an open position. When the valve member is in the open position, medium from the piston chamber is discharged into an outlet chamber located on the opposite side of the coil relative to the armature. An outlet is provided in flow communication with the outlet chamber, for discharging infusion medium from the outlet chamber.

摘要翻译： 一种驱动机构，用于输送能够被电活动以提供电磁场的线圈的输注介质。 线圈围绕沿轴向延伸的活塞通道。 活塞通道提供用于将输注介质连通到位于活塞通道一端的出口腔的通道。 电枢位于线圈附近，位于轴向通道的一侧。 响应于由线圈的激活产生的电磁场，衔铁可朝着前进位置移动。 活塞位于活塞通道内并且响应于电枢到其向前位置的移动而在通道内轴向移动到向前位置。 当线圈未通电时，电枢和活塞向收回位置移动。 在活塞的缩回位置，活塞室形成在活塞和阀构件之间，并且填充有输注介质。 当活塞移动到其前进位置时，活塞室体积减小，并且活塞室内的压力增加到压力将阀构件移动到打开位置的点。 当阀构件处于打开位置时，来自活塞室的介质相对于电枢被排放到位于线圈相反侧的出口腔室中。 提供与出口室流体连通的出口，用于从输出室排出输注介质。

公开(公告)号：US20040224949A1

公开(公告)日：2004-11-11

申请号：US10434266

申请日：2003-05-09

发明人： Seth Pawan ,  Paul Maes

IPC分类号： A61K031/535 ,  A61K009/20 ,  A61K009/22

CPC分类号： A61K9/2866 ,  A61K9/284 ,  A61K31/137

摘要： The present invention provides for a modified release pharmaceutical composition comprising at least one form of tramadol selected from the group consisting of tramadol, enantiomers thereof, pharmaceutically acceptable salts thereof and combinations thereof, the composition exhibiting an in vitro dissolution profile (measured using the USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37null C.) such that after 2 hours, from about 0% up to about 30% (by weight) of the at least one form of tramadol is released, after 4 hours, from about 5% to about 22% (by weight) of the at least one form of tramadol is released, after 6 hours, from about 15% to about 38% (by weight) of the at least one form of tramadol is released, after 8 hours, more than about 40% (by weight) of the at least one form of tramadol is released.

摘要翻译： 本发明提供一种包含至少一种形式的曲马多的改性释放药物组合物，其选自曲马多，其对映异构体，其药学上可接受的盐及其组合，所述组合物显示体外溶出曲线（使用USP Basket 方法在75rpm，在900ml 0.1N HCl中于37℃下进行），使得在2小时后，释放至少一种形式的曲马多的约0％至约30％（重量），4小时后， 释放约5％至约22％（重量）的该曲马多的至少一种形式的曲马朵，6小时后，至少一种曲马多的约15％至约38％（重量）被释放， 8小时后，释放至少一种形式的曲马多的大于约40％（重量）。

公开(公告)号：US20040220552A1

公开(公告)日：2004-11-04

申请号：US10746269

申请日：2003-12-23

申请人： Medtronic, Inc.

发明人： Kenneth T. Heruth ,  Mark S. Lent ,  Justin A. Blanco

IPC分类号： A61K009/22

CPC分类号： A61M5/14276 ,  A61M5/16827 ,  A61M25/007 ,  A61M2025/0007 ,  A61M2025/0057 ,  A61M2025/0073 ,  A61M2202/0464 ,  A61M2205/0244 ,  A61M2205/123 ,  A61M2205/128 ,  A61M2205/3331 ,  A61M2205/3523 ,  A61M2205/50 ,  A61M2210/0693 ,  A61M2210/1003

摘要： Devices, systems and methods for delivering one or more drugs to one or more internal body locations (such as the cerebrospinal fluid) are disclosed. In various aspects, the systems and methods may involve catheters having infusion sections with permeable membranes that develop significant back pressure to enhance uniform delivery of the drug over an infusion section; catheters that have two or more infusion sections spaced apart along the length of the same catheter, catheters that include two or more infusion sections serviced by independent lumens (such that, e.g., different drug solutions can be delivered to the different infusion sections); implantable drug delivery systems with pumps and multiple reservoirs from which drugs can be delivered; systems that are capable of delivering drug solutions with selected densities; etc.

摘要翻译： 公开了用于将一种或多种药物递送到一个或多个内部身体位置（例如脑脊液）的装置，系统和方法。 在各个方面，系统和方法可以包括具有渗透膜的输注部分的导管，其具有显着的背压以增强药物在输注部分上的均匀递送; 具有沿相同导管的长度间隔开的两个或更多个输注部分的导管，包括由独立管腔服务的两个或更多个输注部分的导管（使得例如不同的药物溶液可以被递送到不同的输注部分）; 具有泵和多个储存器的可植入药物递送系统，药物可以从其中递送; 能够递送选定密度的药物溶液的系统; 等等

公开(公告)号：US20040185097A1

公开(公告)日：2004-09-23

申请号：US10762180

申请日：2004-01-21

申请人： Glenmark Pharmaceuticals Ltd.

发明人： Muthaiyyan Esakki Kannan ,  Anandi Krishnan ,  Beena Amol Sapre ,  Chitra Siddharth Shah ,  Atul Vishvanath Patil

IPC分类号： A61K009/22

CPC分类号： A61K9/2031 ,  A61K9/2059

摘要： Disclosed is a controlled release modifying complex for solid oral controlled release pharmaceutical compositions suitable for once-a-day administration. The composition comprises an active pharmaceutical ingredient, a release modifying complex and other required pharmaceutically acceptable excipients. The release modifying complex comprises a primary release modifying agent, a secondary release modifying agent and an auxiliary release modifying agent or varying combinations thereof, wherein said primary, secondary and auxiliary release modifying agents are present in amounts that synergistically effect and extend the release of active pharmaceutical ingredient.

摘要翻译： 公开了一种适用于每天一次给药的固体口服释药药物组合物的控释缓释复合物。 组合物包含活性药物成分，释放改性复合物和其它所需的药学上可接受的赋形剂。 释放改性复合物包含一级释放调节剂，二级释放改性剂和辅助释放调节剂或其不同组合，其中所述初级，次级和辅助释放调节剂以协同作用和延长活性物质释放的量存在 药物成分。

公开(公告)号：US20040185096A1

公开(公告)日：2004-09-23

申请号：US10745950

申请日：2003-12-23

申请人： Euro-Celtique S.A.

发明人： Benjamin Oshlack ,  Mark Chasin ,  Hua-Pin Huang

IPC分类号： A61K009/22

CPC分类号： A61K9/1635 ,  A61K9/145 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/1694 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/2095 ,  Y10S514/951 ,  Y10S514/962

摘要： A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.

公开(公告)号：US20040166157A1

公开(公告)日：2004-08-26

申请号：US10783155

申请日：2004-02-20

申请人： Pfizer Inc

发明人： Avinash G. Thombre

IPC分类号： A61K009/22

CPC分类号： A61K9/0056 ,  A23K40/20 ,  A23K40/30 ,  A23K50/00 ,  A23K50/40 ,  A61K9/2077 ,  A61K9/2081

摘要： The invention pertains to chewable controlled-release multiparticulate pharmaceutical compositions for companion animals and method of making same.

摘要翻译： 本发明涉及用于伴侣动物的咀嚼型控释多颗粒药物组合物及其制备方法。

公开(公告)号：US20040166146A1

公开(公告)日：2004-08-26

申请号：US10732086

申请日：2003-12-10

申请人： University of Florida ,  International Technology Center

发明人： Paul H. Holloway ,  Gary McGuire ,  Olga A. Shenderova ,  John Reynolds ,  Kirk S. Schanze ,  James Boncella

IPC分类号： A61K009/70 ,  A61K009/22

CPC分类号： A61N5/0616 ,  A61F15/00 ,  A61N5/062 ,  A61N2005/0645 ,  A61N2005/065 ,  A61N2005/0653

摘要： A phototherapy bandage capable of providing radiation to a localized area of a patient for accelerating wound healing and pain relief, photodynamic therapy, and for aesthetic applications. The phototherapy bandage may include a flexible light source that is continuous across the bandage for providing a selected light, such as a visible light, a near-infrared light, or other light, having substantially similar intensity across the bandage. The bandage may also be flexible and capable of being attached to a patient without interfering with the patient's daily routine. The phototherapy bandage may easily conform to the curves of a patient and may come in a variety of exterior shapes and sizes.

摘要翻译： 光疗绷带能够向患者的局部区域提供辐射，以加速伤口愈合和疼痛缓解，光动力疗法和美学应用。 光疗绷带可以包括在绷带上连续的柔性光源，以提供在整个绷带上具有基本类似强度的所选择的光，例如可见光，近红外光或其他光。 绷带也可以是柔性的并能够连接到患者而不干扰患者的日常生活。 光疗绷带可以容易地符合患者的曲线，并且可以具有各种外形和尺寸。

公开(公告)号：US20040156897A1

公开(公告)日：2004-08-12

申请号：US10770290

申请日：2004-02-02

发明人： Yihong Qiu ,  J. Daniel Bollinger ,  Howard S. Cheskin ,  Sandeep Dutta ,  Kevin R. Engh ,  Richard P. Poska

IPC分类号： A61K009/22 ,  A61K031/19

CPC分类号： A61K9/2054 ,  A61K9/2009 ,  A61K9/2018 ,  A61K31/19

摘要： A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior arts. This formulation minimnizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.

摘要翻译： 已经发现了适用于每日一次施用丙戊酸酯化合物如新戊酸钠的新的口服聚合物控释制剂。 该配方表现出相对于现有技术的缓释丙戊酸酯制剂的显着优点。 该配方使24小时给药期间丙戊酸钠和谷氨酸血浆水平之间的变化最小化。 一旦达到稳态水平，该配方就遵循零级释放模式，从而产生基本平坦的丙戊酸血浆水平。 这导致消耗这种制剂的患者的副作用发生率显着降低。